Case: Ampio Pharmaceuticals, Inc.
Contact: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

August 8, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE: AMPE) concerning potential securities law violations.  Investors who purchased Ampio securities may be affected.

On March 15, 2018, after the market closed, Ampio issued a press release reporting that its “[p]ivotal trial, AP-003-C, demonstrated positive results for both primary and secondary endpoints with Ampion™ treatment in severe osteoarthritis of the knee (OAK).”  Following this news, Ampio shares increased by 9.5% to close at $2.65 per share on March 16, 2018.

On August 7, 2018 after the market closed, Ampio filed a Form 8-K with the SEC providing a regulatory update of the FDA’s review of the Company’s lead drug candidate Ampion™. According to the filing, the Company met with the FDA in July 2018 and subsequently received a letter in response to the meeting.  Further, according to the filing, the FDA indicated to Ampio that “the AP-003-A study alone does not appear to provide sufficient evidence of effectiveness to support a BLA” and “the FDA does not consider the AP-003-C trial to be an adequate and well controlled clinical trial.” 

Following this news, Ampio shares plummeted by $2.24 per share, over 78%, to close at $0.61 per share on August 8, 2018. 

If you are an investor in Ampio and would like to discuss our investigation, please contact us by emailing This e-mail address is being protected from spambots. You need JavaScript enabled to view it or by calling 800-290-1952.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kaplan Fox & Kilsheimer LLP, with offices in New York, San Francisco, Los Angeles, Chicago and New Jersey, has many years of experience in prosecuting investor class actions. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.  If you have any questions about this Notice, the action, your rights, or your interests, please contact:

Donald R. Hall
KAPLAN FOX & KILSHEIMER LLP
850 Third Avenue, 14th Floor
New York, New York 10022
(800) 290-1952
(212) 687-1980
Fax: (212) 687-7714
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
350 Sansome Street, Suite 400 
San Francisco, California  94104
(415) 772-4700
Fax:  (415) 772-4707
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it